

# *Hypertension Research in Pregnancy*

## **Instructions for Author**

Latest information:

Journal is open from 2013.

### **AIMS AND SCOPE**

*Hypertension Research in Pregnancy* is the official Journal of Japan Society for the study of Hypertension in Pregnancy. This journal publish articles relating clinical research, basic research, pathological and physiological features, animal models, genetic search, fetal programming, medication and case reports in preeclampsia, hypertensive pregnancy and related conditions such as intrauterine growth restriction, malnutrition and obesity, obstetrical emergency, cardiovascular disease or women's long term health care. We accept submissions from all over the world.

### **ACCEPTANCE**

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by anonymous reviewers and the Editor. The Editorial Board reserves the right to refuse any material for publication and advises that authors should retain copies of submitted manuscripts and correspondence as material cannot be returned. Final acceptance or rejection rests with the Editorial Board.

### **SUBMISSION OF MANUSCRIPTS**

All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor or the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision. Manuscripts must be submitted via e-mail to the Editorial Office of *Hypertension Research in Pregnancy* at the address below:

Editorial Office of *Hypertension Research in Pregnancy*

Sanbancho KS building, Sanbancho 2, Chiyoda-ku

Tokyo 102-0075, Japan

**Email: [jsshp@secretariat.ne.jp](mailto:jsshp@secretariat.ne.jp)**

Tel: +81 3 32638697 Fax: +81 3 3263 8693

### **COVERING LETTER**

Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication else-where. This must be stated in the covering letter.

The covering letter must contain an acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified.

Authors must state their study does not violate the policies and/or procedures established by journal such as those described in 'Specific Inappropriate Acts in Publication Process' and also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004), available at <http://www.wma.net/en/30publications/10policies/b3/index.html>. Nonetheless the research has been approved by Ethic Committee, Associate Editors may reject manuscripts when editors judge there has been a problem ethically. All investigations on human subjects must include a statement that the subject gave informed consent and patient anonymity should be preserved. In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) prior to publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editorial Board recognizes that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to

demonstrate that this exception applies in their case. Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research. Authors should declare any financial support or relationships that may pose potential conflict of interest.

## POTENTIAL CONFLICT OF INTEREST

Authors should declare any financial support or relationship that may pose conflict of interest as a potential Conflict of Interest Statement in the Conflict of interest section of your manuscript and cover letter according to the new guideline and confirm that the results of this manuscript have not been distorted by research funding or conflicts of interest. Please visit this link for further details: [Disclosure form](#). Completion and inclusion of Disclosure Form is obligatory with the submission of all categories of article. If the form is not included or complete, the manuscript will not be considered for peer review.

## COPYRIGHT

Papers accepted for publication become the exclusive license of the Japan Society for the study of Hypertension in Pregnancy, and authors are asked to sign a transfer of Exclusive License Form when submitting a manuscript. In signing the transfer of Exclusive License Form it is assumed that authors have obtained permission to use any copyrighted or previously published material. In principle, the corresponding author must mail or fax the Exclusive License Form to the Editorial office immediately; manuscripts cannot be reviewed until we receive this form from the authors. In the event that the manuscript is rejected, the form is rendered invalid. All authors must read and agree to the conditions outlined in the [Exclusive License Form](#). It is the responsibility of the corresponding author to ensure that every author of the paper has signed the Exclusive License Form.

## PREPARATION OF THE MANUSCRIPT

Manuscripts must be submitted in English **with 12pt text font size**. Submission should be, double-space, on one side only of A4 paper. The top bottom and side margins should be 30 mm. All the pages should be numbered consecutively in the top right-hand corner, beginning with the title page. Indent new paragraphs. Turn the hyphenation option off, including only those hyphens that are essential to the meaning. After submission, authors cannot be changed or modified.

### Original articles:

Original articles should provide full-length report of current research in either basic or clinical science.

- The length of an article (including references, tables and appendices etc.) should **not exceed 5000 words**.
- The maximum number of authors is 10. If you wish to include more than 10 authors, please explain the reason in your cover letter and describe the individual contribution of each author.
- The abstract should be **no more than 200 words**.

### Case reports:

Case reports should provide new information that enhances our knowledge of the clinical aspects of hypertension in pregnancy. Information that can be linked to the patients' identification must be carefully masked.

- Case reports should **not exceed 2000 words, 10 references and 2 tables and/or figures**.
- The maximum number of authors is 6. If you wish to include more than 6 authors, please explain the reason in your cover letter and describe the individual contribution of each author.
- The abstract should be **no more than 150 words**.

### Video articles:

Video images

Authors should submit Video images according to the requirements listed in the Video Format section. Print readers will be alerted that the online version contains the full-length video.

Specifications:

Video images should consist of the following headings: Introduction, Case summary or Techniques, and Discussion. The length of an article (including references, legends, tables and appendices etc.) should not exceed 2,000 words.

No more than 2 videos  
No more than 2 tables and/or figures  
Authors should insert the words “Video image(s): ...” at the beginning of their title.  
A legend of video image with 200 words or less  
A legend of figure with 50 words or less  
No more than 10 references.  
The maximum number of authors is 6.  
No abstract.

#### Video Format:

Submit videos as separate supplemental files with your original manuscript submission.  
A brief description of each video, titled “Video legend,” should be uploaded as a separate supplemental file.  
Videos should be named in the order of their text citation (e.g., video1.mov). If a video is directly related to a figure or table, name it accordingly (e.g., Fig4video3.mov). Avoid lengthy file names.  
Preferred video formats include .wmv, .mpg, and .mov files.  
Videos must be no larger than 50 MB.

#### **Letters to the Editor:**

Two styles of Letter to the Editor will be considered for publication:

- i) Letters that reference an article published in *Hypertension Research in Pregnancy*. Letters are to be submitted online no more than 1 year after the date of the issue in which the related article appeared.
- ii) Discourse that sheds light on the understanding of the study of hypertension in pregnancy. This should be structured as a letter to the Editor-in-Chief.

Letters should be brief and contain no more than 400 words and 1–4 references. All data presented in the letter must be fully citable and listed as a supporting reference. Letters should be signed by no more than 3 authors.

#### **Reviews, Editorial Notes, Workshop Reports, and Statements of the Society:**

These articles are usually solicited by the editors.

#### **Style:**

Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’, as presented at <http://www.ICMJE.org>. The Journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary. All measurements must be given in SI units. Abbreviations should be used sparingly and only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. However, for well-known species, the scientific name may be omitted from the article title. If no common name exists in English, the scientific name should be used only. Drugs should be referred to by their generic names, rather than brand names.

#### **Equations:**

Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

#### **PARTS OF THE MANUSCRIPT**

In general, manuscripts should be presented in the following order:

- Title page
- Abstract and key words
- Introduction
- Materials and Methods

- Results
- Discussion
- Acknowledgments
- Conflict of interest
- References
- Tables (each table complete with title and footnotes)
- Figure legends
- Figures
- (Appendices)

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

#### **Title page:**

Title page should contain:

- Title: The title should be short, informative and contain the major key words.
- Full names of the authors.
- Addresses of the institutions at which the work was carried out together with.
- Full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript, proofs and requests for offprints should be sent. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote.
- **A short running title (fewer than 40 characters, including spaces)**

#### **Abstract and key words:**

- All articles except case reports must have a structured abstract that states in **200 words or fewer** the purpose, basic procedures, main findings and principal conclusions of the study. Divide the abstract with the following headings: **Aim, Methods, Results, Conclusions.**
- Case reports should have an unstructured abstract of **150 words or fewer.**
- The abstract should not contain abbreviations or references.
- **Three to five key words** (for the purposes of indexing) should be supplied below the abstract, **in alphabetical order**, and should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list (<http://www.nlm.nih.gov/mesh/meshhome.html>).

#### **Text:**

Authors should use subheadings to divide the sections of their manuscript:

**Introduction, Materials and Methods, Results, Discussion.**

#### **Acknowledgments:**

The source of financial grants and other funding should be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not allowed.

#### **Conflict of interest:**

At the time of submission, the Corresponding author must include a disclosure statement in the body of the manuscript. The statement will describe all of the authors' relationships with companies that may have a financial interest in the information contained in the manuscript. This information should be provided under the heading titled 'Conflict of interest' which should appear after the 'Acknowledgements' section and before the 'References' section. The absence of any interest to disclose must also be stated.

#### **References:**

The Vancouver system of referencing should be used. In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited only in tables or figure legends, number them according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in order

of appearance in the text.

Cite the names of all authors when there are 6 or fewer; **when 7 or more list the first 3 followed by et al.**

Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data).

Standard Journal Article:

1. Watanabe K, Naruse K, Tanaka K, Metoki H, Suzuki Y. Outline of Definition and Classification of “Pregnancy induced Hypertension (PIH)”. *Hypertens Res Pregnancy*. 2013; 1: 3–4.
2. Uchikura Y, Matsubara K, Matsubara Y, et al. Nucleated red blood cells are involved in endothelial progenitor cell proliferation in umbilical venous blood of preeclamptic patients. *Hypertens Res Pregnancy*. 2013; 1: 46–51.

Standard journal article using DOI; articles published online in advance without volume, issue, or page number. The DOI will remain valid and allow an article to be tracked even after its allocation to an issue. (More information about DOIs: <http://www.doi.org/faq.html>):

3. Furuya R, Takahashi R, Furuya S, et al. Is urethritis accompanied by seminal vesiculitis? *Int J Urol*. 2009. doi:10.1111/j.1442-2042.2009.02314.x

Book:

4. Rock JA, Thompson JD. eds. *Telende’s Operative Gynecology*, 8th edn. Philadelphia: Lippincott-Raven, 1996.

Chapter in a Book:

5. Lindheimer MD, Katz AL. Fluid and electrolytes metabolism in normal and abnormal pregnancy. In: Arieff AL, DeFronzo RA. eds. *Fluid, Electrolytes, and Acid Base Disorders*, 2nd edn. New York: Churchill Livingstone, 1995; 839–875.

Website:

6. US Environmental Protection Agency. Polybrominated diphenylethers (PBDEs). Available from URL: <http://www.epa.gov/oppt/pbde/>. Accessed March 1, 2013.

### Tables:

Each table should be given on a separate page. Tables should be submitted in the manuscript file at the conclusion of the reference list and before the figure legends. All tables should be created as **double-spaced text in Microsoft Word** and **vertical lines should not be used** to separate columns. Any table submitted as an Excel spreadsheet, .jpg file, or .tiff file will be returned for replacement.

Tables should be self-contained and complement, but not duplicate, information contained in the text. Tables should be numbered consecutively in Arabic numerals (Table 1, Table 2, etc.). Each table should be presented with a comprehensive but concise legend. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and \*, \*\*, \*\*\* should be reserved for *P*-values. Statistical measures such as SD or SEM should be identified in the headings. The table and its legend/footnotes should be understandable without reference to the text.

### Figure legends:

Legends should be self-explanatory and typed on a separate page. The legend should incorporate definitions of any symbols used and all abbreviations and units of measurement should be explained so that the figure and its legend are understandable without reference to the text. (Provide a letter stating exclusive license authorization if figures have been reproduced from another source.)

### Figures:

All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text (Figure 1, Figure 2A, etc.).

**Figures should be supplied as separate image files (i.e. TIFF [.tiff], JPEG [.jpg], PDF [.pdf], PowerPoint [.ppt]).**

and is not embedded in the text or pasted into a Microsoft Word file. All labeling should be in a **sans-serif font (e.g. Calibri)**.

It is important that the printed symbols and lines should retain their clarity. To achieve this the following points should be considered:

- **The symbols used for plotting data points** should be chosen from the following set if possible.  
○ ● △ ▲ □ ■ ◇ ◆ ▽ ▼ + ×
- The explanation of the symbols must be given as a key in the Figure itself and **not in the Figure legend**.
- Line figures should be supplied as sharp, **black and white graphs or diagrams**, drawn professionally or with a computer graphics package; lettering should be included.
- Some Shading may not reproduce after reduction. Please make shading as 'coarse' as possible. The preferred order to shading of histogram columns is: **open (clear), closed (solid), cross-hatched (lines one way), heavily stippled, and other (if required)**.

Individual images forming a composite figure should be of equal contrast, to facilitate printing, and should be accurately squared. Images need to be cropped sufficiently to prevent the subject being recognized, or an eye bar used. Magnifications should be indicated using a scale bar on the illustration. Images should be supplied as high resolution (at least 300 dpi) files. Digital images supplied only as low-resolution print-outs and/or files cannot be used.

### Appendices:

These should be placed at the end of the paper, numbered in Roman numerals and referred to in the text. If written by a person other than the author of the main text, the writer's name should be included below the title.

### ABBREVIATIONS:

The following abbreviations or symbols may be used without explanation; others should be defined **when first introduced in the text**.

°	degree	<b>GMP</b>	guanosine monophosphate
<b>AM</b>	before noon	<b>GTP</b>	guanosine triphosphate
<b>ANOVA</b>	analysis of variance	<b>h</b>	hour; hecto-
<b>ADP</b>	adenosine diphosphate	<b>Hb</b>	hemoglobin
<b>AMP</b>	adenosine monophosphate	<b>IC<sub>50</sub></b>	inhibitory concentration, 50%
<b>ATP</b>	adenosine triphosphate	<b>i.m.</b>	intramuscular
°C	Celsius	<b>i.p.</b>	intraperitoneal
<b>c</b>	centi-	<b>i.u. / IU</b>	international unit
<b>cal</b>	calorie	<b>i.v.</b>	intravenous
<b>cAMP</b>	cyclic AMP	<b>k</b>	kilo-
<b>cDNA</b>	complementary DNA	<b>kcal</b>	kilocalorie
<b>cGMP</b>	cyclic GMP	<b>kDa</b>	kilodalton
<b>cm, cm<sup>2</sup>, cm<sup>3</sup></b>	centimeters	<b>kg</b>	kilogram
<b>cpm</b>	counts per minute	<b>km</b>	kilometer
<b>cRNA</b>	complementary RNA	<b>l</b>	liter
<b>CT</b>	computed tomography	<b>log</b>	logarithm
<b>d</b>	deci-	<b>mol/l</b>	moles/liter (molar)
<b>DNA</b>	deoxyribonucleic acid	<b>m</b>	meter; milli-
<b>DNase</b>	deoxyribonuclease	<b>mEq</b>	milliequivalent
<b>EC<sub>50</sub></b>	50% effective concentration	<b>mg</b>	milligram
<b>ECG</b>	electrocardiogram	<b>min</b>	minute
<b>ED<sub>50</sub></b>	50% effective dose	<b>ml</b>	milliliter
<b>ELISA</b>	enzyme-linked immunosorbent assay	<b>ml/min</b>	milliliters per minute
<b>Eq</b>	equivalent	<b>mm, mm<sup>2</sup>, mm<sup>3</sup></b>	millimeters
<b>g</b>	gram	<b>mmHg</b>	millimeters of mercury
<b>g</b>	gravitational constant	<b>mol</b>	mole

<b>mRNA</b>	messenger RNA	<b>r</b>	correlation coefficient
<b>MRI</b>	magnetic resonance imaging	<b>RBC</b>	red blood cell
<b>n.s.</b>	not significant	<b>RNA</b>	ribonucleic acid
<b>μ</b>	micro-	<b>RNase</b>	ribonuclease
<b>μl</b>	microliter	<b>rpm</b>	revolutions per minute
<b>μmol</b>	micromole	<b>RT-PCR</b>	reverse transcriptase-polymerase chain reaction
<b>n</b>	nano-	<b>s</b>	second
<b>n</b>	number in study or group	<b>s.c.</b>	subcutaneous
<b>nm</b>	nanometer	<b>SD</b>	standard deviation
<b>osmol</b>	osmole	<b>SE</b>	standard error
<b>p</b>	pico-	<b>SEM</b>	standard error of the mean
<b>P</b>	probability	<b>U</b>	unit
<b>PCR</b>	polymerase chain reaction	<b>V</b>	volt
<b>%</b>	percent	<b>WBC</b>	white blood cell
<b>pH</b>	negative log of hydrogen ion concentration	<b>vs.</b>	versus
<b>PM</b>	after noon		

## TRIAL AND RESEARCH GUIDELINES

The Editor recommends the following guidelines for evidence-based reporting of randomized controlled trials, systematic reviews and meta-analyses. For reporting randomized controlled trials refer to the guidelines of The CONSORT Statement: <http://www.consort-statement.org>. For systematic reviews and meta-analyses refer to the guidelines of The PRISMA Statement: <http://www.prisma-statement.org/index.htm>.

## ELECTRONIC FILE OF MANUSCRIPTS

- The entire article (including tables) should be supplied as a single file; **only electronic figures should be supplied as separate files**. The following instructions should be adhered to.
- It is essential that the final, revised version of the accepted manuscript and the electronic file are identical.
- Do not use the carriage return (enter) at the end of lines within a paragraph.
- Turn the hyphenation option off.
- Specify any special characters used to represent non-keyboard characters.
- Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German eszett) for β (Greek beta).
- Use double quotation marks for citations (“ ”), please note that asterisks must not be used (\* \*).
- Use a tab, not spaces, to separate data points in tables.
- If you use a table editor function, ensure that each data point is contained within a unique cell; i.e. do not use carriage returns within cells.
- Digital figures must be supplied as .tiff, .jpg, .pdf, or .ppt files at a resolution of at least 300 dpi.

## PROOFS

Notification of the URL from where to download a PDF (Portable Document Format) typeset page proof, associated forms and further instructions will be sent by email to the corresponding author. Alterations to the text and figures (other than the essential correction of errors) are unacceptable at proof stage and authors may be charged for excessive alterations. The proof should be checked, and approval to publish the article should be emailed to the Publisher within 3 days of receipt. Authors should supply an email address to which the notification can be emailed. If absent, authors should arrange for a colleague to access their email, retrieve the PDF page proof and check and return them to the publisher on their behalf.

## OPEN ACCESS AND ARTICLE PROCESSING CHARGE

*Hypertension Research in Pregnancy* is preparing to publish all articles as open access under the system of J-STAGE (Japan Science and Technology Information Aggregator, Electronic), developed by Japan Science and Technology Agency (JST).

Some part of the publication costs of an article should be paid from an author's research budget, or by their supporting institution, in the form of Article Processing Charges. Publishing an article in *Hypertension Research in Pregnancy* requires Article Processing Charges that will be billed to the submitting author upon acceptance of the article for publication in accordance with the following table. The charges for the articles solicited by the editors are able to be exempted or reduced under the judgment of the Editor-in-Chief.

Corresponding Author is;

In Japanese institution and a member of Japan Society for the study of Hypertension in Pregnancy: JPY 30,000

In Japanese institution but a non-member of Japan Society for the study of Hypertension in Pregnancy: JPY 50,000

In institution other than Japan: JPY 30,000

## COLOR CHARGES

Color figures online only are free, but there is a charge for printing figures in color. Expense for color reproduction in print is based on the number of journal pages with color figures. Each journal page with color figures costs JPY 30,000.

## OFFPRINTS

A minimum of 50 offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please contact the Editorial Office of Hypertension Research in Pregnancy at the address below:

Editorial Office

*Hypertension Research in Pregnancy*

IWO Bld.3, 1-5-5, Iidabashi, Chiyoda-ku

Tokyo 102-0072, Japan

Email: [jsshp@letterpress.co.jp](mailto:jsshp@letterpress.co.jp)

Tel: +81 3 6261 2707 Fax: +81 3 6261 2708

Price list for reprints /without cover (JPY, including tax)

Number of pages	Number of reprints			
	50	100	150	200
1– 2	10,500	12,000	13,500	15,000
3– 4	16,500	18,000	19,500	21,000
5– 6	18,000	21,000	24,000	27,000
7– 8	19,500	24,000	28,500	33,000
9–10	21,000	27,000	33,000	39,000
11–12	22,500	30,000	37,500	45,000

A minimum of 50 offprints will be provided upon request, at the author's expense.



# *Hypertension Research in Pregnancy*

## **Manuscript Submission Checklist**

Please complete this form as you prepare your submission. **A completed Manuscript Submission Checklist must accompany the submission.** Please see the **Instructions for Author** for additional and more detailed instruction.

**Manuscript title:** .....

**Corresponding author:** .....

### **Format**

- Double-spaced text
- Numbered pages
- Text font size: **12-point**
- In general, manuscripts should be presented in the following order: **Title page, Abstract and key words, Body text (Introduction, Materials and Methods, Results, Discussion), Acknowledgments, Conflict of interest, References, Tables, Figure legends, and Figures.** Figures are supplied in separate files.
- Abbreviations should be defined **when first introduced in the text.**

### **Title page** (include all of the following information)

- Title
- Full names of the authors
- Each author's affiliation during the study
- Corresponding author's contact information (name, highest academic degree [e.g., M.D., Ph.D.], address, email address, telephone and fax numbers)
- A short running title (≤ 40 characters, including spaces)**

### **Abstract and key words**

Abstract word count: ..... words

a structured abstract (all articles except case report): **≤ 200 words**

an unstructured abstract (case report): **≤ 150 words**

- Three to five key words** should be supplied below the abstract, **in alphabetical order.**

### **Body text (Introduction, Materials and Methods, Results, Discussion)**

Main text word count (including references and tables): words

Original Article: **≤ 5000 words**

Case Report: **≤ 2000 words**

- Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

### **Acknowledgments**

- The source of financial grants and other funding should be acknowledged. The contribution of colleagues or institutions should also be acknowledged.

### **Conflict of interest**

- The Corresponding author must include a disclosure statement of any potential conflict of interest in the Conflict of interest section.

## References

- Number references sequentially, in the order that they are cited.
- Cite the names of all authors when there are 6 or fewer; **when 7 or more list the first 3 followed by et al.**

## Tables

- All tables should be created as **double-spaced text in Microsoft Word** (not be supplied as Excel spreadsheets, .jpg, or .tiff files).
- Vertical lines should not be used** to separate columns.
- Each table has a **brief title**.

## Figure legends

- Figure legends should be typed on a separate page.
- Each figure has a **brief title**.

## Figures

- Each figure should be supplied as a separate image file, and is not embedded in the text or pasted into a Microsoft Word file.
- Accepted figure formats: **TIFF (.tiff), JPEG (.jpg), PDF (.pdf), PowerPoint (.ppt)**
- All labeling should be in a **sans-serif font (e.g. Calibri)**.
- The symbols used for plotting data points** should be chosen from the following set if possible: ○ ● △ ▲  
□ ■ ◇ ◆ ▽ ▼ + ×
- The explanation of the symbols must be given as a key in the Figure itself and **not in the Figure legend**.
- Please make shading as 'coarse' as possible. The preferred order to shading of histogram columns is: **open (clear), closed (solid), cross-hatched (lines one way), heavily stippled, and other (if required)**.

## Hypertension Research in Pregnancy

### Disclosure Guideline for Potential Conflict of Interests

Title: \_\_\_\_\_

Authors: \_\_\_\_\_

As of 23rd May 2011, Japan Society for the study of Hypertension in Pregnancy has introduced a new disclosure guideline. All authors are required to disclose any financial relationship (**within the past 12 months**) with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity **that has an interest in subject matter or materials discussed in the manuscripts**.

Authors might consider, as a guide for financial disclosures, reporting interests where the sums concerned are described in the following society's definition:

	Type	No*	Pay to you	Pay to institution**	Name of entity	Comments***
1	Employment/Leadership position/ Advisory role (US\$10,000. – or more)					
2	Stock ownership (Profit of US\$10,000. – or more/ownership of 5% or more of total shares)					
3	Patent royalties/licensing fees (US\$10,000. – or more)					
4	Honoraria (e.g. lecture fees) (US\$5,000. – or more)					
5	Fees for promotional materials (e.g. manuscript fee) (US\$5,000. – or more)					
6	Research funding (US\$20,000. – or more)					
7	Others (e.g. trips, travel, or gifts, which are not related to research) (US\$500. – or more)					

\* Please  if you do not have anything to claim here.

\*\* This means money that your institution received for your efforts on this study.

\*\*\* Use this section to provide any needed explanation.

Authors do not need to report the sums concerned.

When your manuscript is accepted for publication, all of the disclosure will appear in your article as "Disclosure" in *Hypertension Research in Pregnancy* as follow.

#### Disclosure Statement

Potential Conflict of Interest Statement as follows:

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; No author has any potential conflict of interest. In signing this document, the corresponding author confirms all information above.

\_\_\_\_\_  
Corresponding Author's Name/Signature

\_\_\_\_\_  
Date Signed

# Hypertension Research in Pregnancy

## Exclusive License Form

Please return the signed form to:

Editorial Office of *Hypertension Research in Pregnancy*  
Japan Society for the study of Hypertension in Pregnancy  
IWO Bld.3, 1-5-5, Iidabashi, Chiyoda-ku, Tokyo, 102-0072, Japan  
Email: [jsshp@letterpress.co.jp](mailto:jsshp@letterpress.co.jp)

**Author's name:** .....

**Author's address:** .....

**Title of article ("Article"):** .....

**Manuscript No.:** .....

**Names of all authors in the order in which they appear in the Article:** .....

### All authors are required to sign this form

**BOX A: to be completed if copyright belongs to you**

**BOX B: to be completed if copyright belongs to your employer (e.g. HMSO, CSIRO)**

The copyright holder grants Japan Society for the study of Hypertension in Pregnancy an exclusive license to publish the Article including the abstract in printed and electronic form, in all languages, and to administer subsidiary rights agreements with third parties for the full period of copyright and all renewals, extensions, revisions and revivals.

#### Print Name of Copyright holder:

This will be printed on the copyright line on each page of the Article. It is your responsibility to provide the correct information of the copyright holder.

**BOX C: to be completed if the Article is in the public domain (e.g. US Federal Government employees)**

You certify that the Article is in the public domain. No license to publish is therefore necessary.

**Signature:**

.....

**Print name:** .....

**Date:** .....

**Signature:**

.....

**Print name:** .....

**Date:** .....

**Signature:**

.....

**Print name:** .....

**Date:** .....

**Signature:**

.....

**Print name:** .....

**Date:** .....

**Signature:**

.....

**Print name:** .....

**Date:** .....

**Signature:**  
.....

**Print name:** .....

**Date:** .....

**Signature:**  
.....

**Print name:** .....

**Date:** .....

**Signature:**  
.....

**Print name:** .....

**Date:** .....

**Signature:**  
.....

**Print name:** .....

**Date:** .....

**Signature:**  
.....

**Print name:** .....

**Date:** .....

If your employer claims copyright in your work, this form must also be signed below by a person authorized to sign for and on behalf of your employer, as confirmation that your employer accepts the terms of this license.

Signature (on behalf of the employer of the author (s)):  
.....

Print name: .....

Print name of employer: .....

Date: .....

The rights conveyed in this license will only apply upon acceptance of your Article for publication.

Please return the signed form to:  
Editorial Office of *Hypertension Research in Pregnancy*  
Japan Society for the study of Hypertension in Pregnancy  
IWO Bld.3, 1-5-5, Iidabashi, Chiyoda-ku, Tokyo, 102-0072, Japan  
Email: [jsshp@letterpress.co.jp](mailto:jsshp@letterpress.co.jp)